vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $20.0M, roughly 1.0× AGIOS PHARMACEUTICALS, INC.). Entrada Therapeutics, Inc. runs the higher net margin — -84.4% vs -541.1%, a 456.7% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -65.2%). Entrada Therapeutics, Inc. produced more free cash flow last quarter ($-39.7M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 6.4%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
AGIO vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $20.6M |
| Net Profit | $-108.0M | $-17.3M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | -106.0% |
| Net Margin | -541.1% | -84.4% |
| Revenue YoY | 86.1% | -65.2% |
| Net Profit YoY | -11.9% | -173.8% |
| EPS (diluted) | $-1.86 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.5M | — | ||
| Q1 25 | $8.7M | $20.6M | ||
| Q4 24 | $10.7M | $37.4M | ||
| Q3 24 | $9.0M | $19.6M | ||
| Q2 24 | $8.6M | $94.7M | ||
| Q1 24 | $8.2M | $59.1M |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | — | ||
| Q2 25 | $-112.0M | — | ||
| Q1 25 | $-89.3M | $-17.3M | ||
| Q4 24 | $-96.5M | $1.1M | ||
| Q3 24 | $947.9M | $-14.0M | ||
| Q2 24 | $-96.1M | $55.0M | ||
| Q1 24 | $-81.5M | $23.5M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | — | ||
| Q2 25 | -1020.1% | — | ||
| Q1 25 | -1222.0% | -106.0% | ||
| Q4 24 | -1165.3% | -15.7% | ||
| Q3 24 | -1146.9% | -110.7% | ||
| Q2 24 | -1228.3% | 56.4% | ||
| Q1 24 | -1124.3% | 35.7% |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | — | ||
| Q2 25 | -899.4% | — | ||
| Q1 25 | -1023.3% | -84.4% | ||
| Q4 24 | -899.6% | 3.0% | ||
| Q3 24 | 10574.7% | -71.7% | ||
| Q2 24 | -1115.7% | 58.1% | ||
| Q1 24 | -995.8% | 39.7% |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | — | ||
| Q2 25 | $-1.93 | — | ||
| Q1 25 | $-1.55 | $-0.42 | ||
| Q4 24 | $-1.44 | $-0.20 | ||
| Q3 24 | $16.22 | $-0.35 | ||
| Q2 24 | $-1.69 | $1.55 | ||
| Q1 24 | $-1.45 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $417.3M |
| Total Assets | $1.3B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | — | ||
| Q2 25 | $80.9M | — | ||
| Q1 25 | $79.0M | $67.8M | ||
| Q4 24 | $76.2M | $101.2M | ||
| Q3 24 | $253.7M | $78.0M | ||
| Q2 24 | $84.5M | $185.3M | ||
| Q1 24 | $118.8M | $68.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.5B | $417.3M | ||
| Q4 24 | $1.5B | $428.7M | ||
| Q3 24 | $1.6B | $422.4M | ||
| Q2 24 | $660.5M | $429.9M | ||
| Q1 24 | $743.9M | $269.4M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | $486.5M | ||
| Q4 24 | $1.7B | $526.3M | ||
| Q3 24 | $1.8B | $554.6M | ||
| Q2 24 | $773.1M | $582.0M | ||
| Q1 24 | $849.7M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $-38.5M |
| Free Cash FlowOCF − Capex | $-97.3M | $-39.7M |
| FCF MarginFCF / Revenue | -487.5% | -192.9% |
| Capex IntensityCapex / Revenue | 5.6% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | — | ||
| Q3 25 | $-88.2M | — | ||
| Q2 25 | $-77.1M | — | ||
| Q1 25 | $-111.5M | $-38.5M | ||
| Q4 24 | $-133.2M | $-31.6M | ||
| Q3 24 | $-84.2M | $-24.3M | ||
| Q2 24 | $-72.6M | $39.8M | ||
| Q1 24 | $-99.9M | $-25.5M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | — | ||
| Q1 25 | $-112.3M | $-39.7M | ||
| Q4 24 | $-134.1M | $-32.2M | ||
| Q3 24 | $-84.6M | $-24.9M | ||
| Q2 24 | $-72.7M | $38.8M | ||
| Q1 24 | $-100.0M | $-26.4M |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | — | ||
| Q1 25 | -1286.4% | -192.9% | ||
| Q4 24 | -1250.1% | -86.2% | ||
| Q3 24 | -944.2% | -127.3% | ||
| Q2 24 | -844.4% | 41.0% | ||
| Q1 24 | -1221.2% | -44.6% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 8.8% | 5.6% | ||
| Q4 24 | 9.0% | 1.7% | ||
| Q3 24 | 4.7% | 3.3% | ||
| Q2 24 | 1.8% | 1.1% | ||
| Q1 24 | 1.7% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
